Clinical Impact of a Germline CD19 Variant on Treatment Outcome After CAR-T Cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma.

Cancers (Basel) · 2026 · PMC13360018 · PMID 42449653

Europe PMC DOI

hedged sentence

0.0750

closest p · 1.5× alpha

0.0750

boldest claim

The sentences

did not reach statistical significancep = 0.075so close (0.05 < p ≤ 0.1)

While the log-rank test did not reach statistical significance ( p = 0.075), the Gehan–Breslow–Wilcoxon test indicated a significant difference in OS between the CD19 genotype groups ( p = 0.045).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.